What is the out-of-pocket price of lorlatinib after medical insurance reimbursement?

Lorlatinib is a third-generation ALK inhibitor that is widely used to treat patients with ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC). As a highly effective targeted drug, lorlatinib has been approved for marketing in China and has been included in the national medical insurance drug catalog, which has alleviated patients' medication burden to a certain extent. However, even if it is included in medical insurance, the actual out-of-pocket price still varies depending on regional policies, reimbursement ratios and personal insurance status, and patients still need to understand it in advance.

According to current public information, the market price of lorlatinib before medical insurance is approximately 1 to 2000 yuan per box (generally 30 tablets). After being included in medical insurance, if calculated based on the common ratio of medical insurance reimbursement of 60% to 70%, the patient's out-of-pocket cost per box ranges from approximately 3,000 yuan to 6,000 yuan. However, the specific amount needs to be confirmed based on the medical insurance reimbursement policies of different cities, hospital levels and the type of medical insurance held by the patient (urban and rural residents medical insurance or employee medical insurance). Therefore, it is recommended that patients go to the hospital where they are treated or the medical insurance designated pharmacy for detailed consultation.

In addition to the domestic market, some patients will also consider purchasing original drugs or generic drugs overseas to reduce their financial burden. The relatively affordable ones are the original drugs produced in Turkey, which are priced at about 7,000 yuan, which is very cost-effective. However, the original drugs in Hong Kong, China, are priced as high as about 3 yuan per box due to differences in channels and pricing. If you choose generic drugs, such as Lucius from Laos or INCEPTA from Bangladesh, the price is even lower, generally between 1,000 yuan and 1,500 yuan. However, you need to ensure that the source is regular when purchasing to ensure the safety of medication.

In general, the out-of-pocket price of lorlatinib after medical insurance reimbursement is significantly lower than before medical insurance, which greatly reduces the financial pressure, especially for long-term treatment patients. Patients should weigh the relationship between price, safety and legality when deciding where to purchase drugs. If conditions permit, give priority to purchasing drugs through medical insurance or legal channels recommended by doctors, and maintain regular follow-up visits to monitor efficacy and side effects to ensure the continuity and safety of treatment.

Reference materials:https://www.drugs.com/